Why Are Iveric Bio Shares Surging
- Iveric Bio Inc
ISEE
stock is trading almost 50% higher as the investors are cheering Stifel's initiated coverage on Iveric Bio with a Buy rating and a price target of $22.00. - Analyst Annabel Samimy comments that, though the Company is not a first mover in the still untapped Geographic Atrophy (GA) market, Iveric could very well be the leading treatment for this indication.
- Zimura has demonstrated high statistical significance in the pivotal study and can potentially emerge as the only treatment that could prevent vision loss and function. .
- Together, we see ISEE as building a unique platform for untapped retinal diseases," mentions the analyst.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.